AbbVie's stock performance shows that investors who bought shares during periods of market pessimism, such as after the Allergan selloff in 2019, earned higher returns than those who bought on positive drug approval news. For example, buying AbbVie after Rinvoq's approval during a selloff yielded better gains than buying after Skyrizi's approval. Despite good news driving stock prices up, the best entry points were often during uncertainty or fear. AbbVie has consistently outperformed the S&P 500 over various time frames, and upcoming product launches like an injectable Skyrizi for Crohn's disease could influence future performance. Investors should note that entry price mattered more than holding period in maximizing returns.
AbbVie trades near its 52-week high at USD 265.60, just shy of the peak at USD 266.40, as of Oct 06, 2026 19:45 WIB. Despite a slight 1-day dip of 0.06%, the stock maintains strong investor interest with 80% of Pluang orders being buys. Its dividend yield of 2.6% and a typical hold time of 94 days on Pluang highlight steady engagement compared to its 52-week low of USD 197.38, underscoring the value of timing entry points as discussed in the news.
